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Abstract: Subthreshold anxiety and subthreshold depressive symptoms often
co-occur in the general population and in primary care. Based on their asso-
ciated significant distress and impairment, a psychiatric classification seems
justified. To enable classification, mixed anxiety depression (MAD) has been
proposed as a new diagnostic category in DSM-5. In this report, we discuss
arguments against the classification of MAD. More research is needed before
reifying a new category we know so little about. Moreover, we argue that in
patients with MAD symptoms and a history of an anxiety or depressive dis-
order, symptoms should be labeled as part of the course trajectories of these
disorders, rather than calling it a different diagnostic entity. In patients with
incident co-occurring subthreshold anxiety and subthreshold depression,
subthreshold categories of both anxiety and depression could be classified to
maintain a consistent classification system at both threshold and subthreshold
levels.
Key Words: Anxiety, classification, depression, diagnosis, mixed anxiety
depression.
(J Nerv Ment Dis 2012;200: 495Y498)
Depressive and anxiety symptoms are extremely common in thegeneral population and in primary care (Batelaan et al., 2007;
Cuijpers et al., 2004; Katon and Roy-Byrne, 1991; Olfson et al., 1996;
Ormel et al., 1993; Rucci et al., 2003; Zinbarg et al., 1994), and they
frequently co-occur (Das-Munshi et al., 2008; Piccinelli et al., 1999;
Preisig et al., 2001; Spijker et al., 2010). Co-occurring subthreshold
depression and subthreshold anxiety are associated with impaired
functioning (Das-Munshi et al., 2008; Preisig et al., 2001; Roy-Byrne
et al., 1994). For example, one fifth of work loss days occurred in
those with co-occurring subthreshold depression and subthreshold
anxiety (Das-Munshi et al., 2008). Moreover, seeking treatment is
common in this group, suggesting significant levels of distress
(Preisig et al., 2001; Roy-Byrne et al., 1994). For example, of those
with comorbid subthreshold anxiety and subthreshold depression,
as diagnosed on a lifetime basis, 63% had ever sought treatment for
their complaints (Preisig et al., 2001). Individuals with co-occurring
subthreshold anxiety and subthreshold depression lack a specific
psychiatric diagnosis in the DSM classification system, whereas a
psychiatric classification may be justified based on the associated
significant distress or associated impairment.
To enable classification of those with co-occurring sub-
threshold anxiety and subthreshold depression, a distinct diagnosis
has been proposed. Since 1992, classifying mixed anxiety and de-
pressive disorder is possible using the ICD-10 classification system
(World Health Organization, 1992). However, in ICD-10, the criteria
have not been defined very precisely. According to the ICD-10, the
category of Mixed Anxiety and Depressive Disorder should be used
‘‘when symptoms of anxiety and depression are both present, but
neither is clearly predominant, and neither type of symptom is
present to the extent that justifies a diagnosis if considered sepa-
rately. When both anxiety and depressive symptoms are present and
severe enough to justify individual diagnoses, both diagnoses should
be recorded and this category should not be used’’ (World Health
Organization, 1992). The appendix of theDSM-IV included research
criteria for mixed anxietyYdepressive disorder that are more specific
(Table 1) (American Psychiatric Association, 1994). Recently, cri-
teria have been proposed to be included in DSM-5 using the term
mixed anxiety depression (MAD) (American Psychiatric Association,
2012a). For DSM-5, the draft diagnostic criteria of MAD read as
follows. Three or four of the symptoms of major depression must
be present, which must include depressed mood and/or anhedonia.
These symptoms should be accompanied by anxious distress, de-
fined as having two or more of the following: irrational worry,
preoccupation with unpleasant worries, having trouble relaxing,
motor tension, and fear that something awfulmay happen. Symptoms
must have lasted at least 2 weeks, are occurring at the same time, and
no other DSM diagnosis of anxiety or depression must be present
(American Psychiatric Association, 2012a) (Table 2). These criteria
are still tentative. For example, it has not been decided whether the
minimum number of required depressive symptoms should be three
or four. Field trials investigating the feasibility, clinical utility, and re-
liability of the draft criteria of MAD have been conducted. The pro-
posed criteria may be revised after the field trials (American Psychiatric
Association, 2012b).
Slightly different names have been used for this disease con-
cept. For reasons of clarity, the termmixed anxiety depression (MAD)
will be used throughout this article.
Including such a diagnosis in DSM-5 may have several ad-
vantages. A diagnosis ofMADmay raise awareness about the frequent
co-occurrence of subthreshold anxiety and depression and its clinical
and public health significance. Moreover, it would provide the oppor-
tunity to investigate the prevalence, consequences, and course while
using standardized criteria. By facilitating research, the development
of (cost-) effective treatment strategies may be accelerated, as a result
of which the burden of disease generated by MAD could be reduced.
Finally, the DSM classification system would be more compatible with
the ICD classification system, although the definitions of these two
entities remain divergent. Although acknowledging that co-occurring
subthreshold anxiety and depression warrant clinical attention, we se-
riously question whether including MAD in the classification system
of the DSM-5 is the most rational and valid option available. On the
basis of previous research, we discuss several concerns regarding the
concept of MAD: a) divergent results of previous research, b) incon-
sistency in nomenclature between subthreshold and threshold level,
and c) limited diagnostic stability over time.
DIVERGENT RESULTS OF PREVIOUS RESEARCH
MAD has been investigated using different sets of criteria,
and as a result, previous results on prevalence and course have been
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inconsistent. This hinders a proper assessment of the disease con-
cept. Divergent findings regarding the course are described under
the subheading ‘‘Diagnostic instability over time.’’ Here, we will
elaborate on the prevalence of MAD. Some researchers found MAD
to be a highly prevalent condition (Das-Munshi et al., 2008; Schmidt
et al., 2007; Zinbarg et al., 1994), whereas others reported marginal
prevalence rates (Means-Christensen et al., 2006; Spijker et al., 2010;
Weisberg et al., 2005). For example, we found an annual prevalence
rate of .6% in the general population by administering the Composite
International Diagnostic Interview and by applying criteria almost
similar to the research criteria of DSM-IV, thus excluding those with
a current anxiety disorder or depressive disorder as well as excluding
those with a history of a major depressive disorder, dysthymic dis-
order, panic disorder, or generalized anxiety disorder (Spijker et al.,
2010). By contrast, Das-Munshi et al. (2008) reported a 1-month
prevalence rate of 8.8% in the general population when classifying
MAD in those who scored above the predefined threshold on the
Clinical Interview ScheduleYRevised and who did not meet ICD
criteria of a current anxiety or depressive disorder (Das-Munshi
et al., 2008). These examples show the huge impact of diagnostic
criteria on prevalence rates. When criteria are too strict, the preva-
lence will be marginal. This will limit the clinical utility of the di-
agnosis. When criteria are too loose, there is a risk of false-positives,
that is, of making a diagnosis when this is not indicated. This may
result in an exponential increase in the target population for mental
health care, in unnecessary drug prescriptions or health care visits,
and in a substantial economic burden posed on the health care
system. In theDSM-IV field trials, already high prevalence rates were
reported in primary care when symptoms lasting for at least a month
were required (Zinbarg et al., 1994). In the proposed criteria for
DSM-5, the required duration of symptoms has been lowered to only
2 weeks, which will inflate prevalence rates. In addition, there is no
requirement in the DSM-5 criteria to consider the context in which
the depressive and anxiety symptoms arose. Many stressful life
events may trigger anxiety and depressive symptoms that meet the
2-week duration criterion for MAD, many of which are likely to be a
transient and normal response to these stressful life events and thus
constitute false-positives if the diagnosis of MAD were applied.
At the time of including MAD in the Appendix of DSM-IV
in 1994 (American Psychiatric Association, 1994), Zinbarg et al.
(1994) stated that the sensitivities and specificities associated with
different symptom thresholds should be investigated, as well as the
prevalence in the general population. We think that this statement
still holds true: given the substantial impact of criteria on prevalence,
the limited clinical utility in case of low prevalence rates, and the
potentially adverse consequences in case of many false-positives,
these issues should be addressed before including MAD in DSM-5.
Although MAD is on the list of proposed disorders to be investi-
gated in field trials in large academic clinic settings (American
Psychiatric Association, 2012b), answering the questions above re-
quire investigating MAD in both primary care settings or the general
population, neither of which are included in the DSM-5 Field Trial
samples.
INCONSISTENCY IN NOMENCLATURE BETWEEN
SUBTHRESHOLD AND THRESHOLD LEVELS
Anxiety and depression are highly comorbid at both subthresh-
old and threshold levels (Das-Munshi et al., 2008; De Graaf et al., 2002;
Kessler et al., 2005, 1994; Piccinelli et al., 1999; Preisig et al., 2001;
Spijker et al., 2010), anxiety disorders and depressive disorders share
a genetic vulnerability (Hettema et al., 2006), and diagnostic conver-
sions occur over time from anxiety disorders to depressive disorders
and vice versa (Hagnell and Grasbeck, 1990; Merikangas et al., 2003;
Rhebergen et al., 2011). These findings have raised the fundamental
question of whether it is justified to regard anxiety and depressive
disorders as different disease concepts. Previously, a tripartite model
of anxiety and depressive disorders has been postulated (Clark and
Watson, 1991), consisting of anxiety, depression, and MAD. Accord-
ing to this model, anxiety and depression share the presence of non-
specific general distress or negative affect. In addition, the lack of
positive affect is specific to depression and the presence of hyper-
arousal to anxiety. According to this model, MAD is predominantly
characterized by the presence of nonspecific general distress. In line
with this, a profile analysis has shown that subclinical patients most
often had a nonspecific symptom profile (Barlow and Campbell,
2000). However, previously, we have found little differences between
MAD, pure subthreshold anxiety, and pure subthreshold depression
in terms of sociodemographics, care utilization, functioning, and
2-year course (Spijker et al., 2010). Thereby, the benefits of clas-
sifying MAD over classifying both subthreshold anxiety and sub-
threshold depression can be questioned. It will be possible to classify
subthreshold depression in DSM-5 using the term Subsyndromal
Depressive CNEC, a subcategory of ‘‘Depressive Conditions Not
TABLE 1. Research Criteria for Mixed Anxiety Depressive
Disorder in the Appendix of DSM-IV (American Psychiatric
Association, 1994)
A. Persistent or recurrent dysphoric mood lasting at least 1 month.
B. The dysphoric mood is accompanied by at least 1 month of four
(or more) of the following symptoms:
1. difficulty concentrating or mind going blank
2. sleep disturbance (difficulty falling or staying asleep, or restless,
unsatisfying sleep)
3. fatigue or low energy
4. irritability
5. worry
6. being easily moved to tears
7. hypervigilance
8. anticipating the worst
9. hopelessness (pervasive pessimism about the future)
10. low self-esteem or feelings of worthlessness
C. The symptoms cause clinically significant distress or impairment in
social, occupational, or other important areas of functioning.
D. The symptoms are not due to the direct physiological effects of a
substance (e.g., a drug of abuse, a medication) or a general medical
condition.
E. All of the following:
1. criteria have never beenmet for major depressive disorder, dysthymic
disorder, panic disorder, or generalized anxiety disorder
2. criteria are not currently met for any other anxiety or mood disorder
(including an Anxiety or Mood Disorder, In Partial Remission)
3. the symptoms are not better accounted for by any other mental
disorder
TABLE 2. Proposed Criteria for Mixed Anxiety Depressive
Disorder in DSM-5 (American Psychiatric Association, 2012a)
The patient has three or four of the symptoms of major depression (which
must include depressed mood and/or anhedonia), and they are accom-
panied by anxious distress. The symptoms must have lasted at least
2 weeks, and no other DSM diagnosis of anxiety or depression must be
present, and they are both occurring at the same time.
Anxious distress is defined as having two or more of the following
symptoms: irrational worry, preoccupation with unpleasant worries,
having trouble relaxing, motor tension, fear that something awful may
happen.
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Elsewhere Classified (CNEC)’’ (American Psychiatric Association,
2011), presuming that this diagnosis will be approved as an estab-
lished diagnosis in DSM-5. Although proposed revisions for Unspec-
ified Anxiety Disorder are not available yet (American Psychiatric
Association, 2012c), a similar option for subthreshold anxiety is to
be expected, given that in DSM-IV, subthreshold anxiety can be
classified as Anxiety Disorder Not Otherwise Specified (American
Psychiatric Association, 2012c). If indeed these subthreshold cate-
gories will be approved as established diagnoses in DSM-5, the
category of MAD might be redundant. Probably even more impor-
tant, adding a MAD category would be inconsistent with current
nomenclature in which anxiety and depression are classified sepa-
rately. It would be irrational to add a new diagnosis of co-occurring
anxiety and depression at the subthreshold level while refraining
from such a ‘‘comorbid diagnosis’’ at the threshold level. Rather,
maintaining a consistent classification system at both threshold and
subthreshold levels would be more rational.
LIMITED DIAGNOSTIC STABILITY OVER TIME
At the time of conducting the DSM-IV field trials for MAD,
it was acknowledged that the validity of MAD needed further study
(Zinbarg et al., 1994). To validate a disease concept, diagnostic sta-
bility over time is regarded as important: ‘‘a rose is a rose because
it remains a rose’’ (Goodwin and Guze, 1996). This implies that pro-
dromal symptoms, symptoms in the context of a disorder, and resi-
dual symptoms after remission of the disorder should all be captured
within the same disease concept. However, the disease concept of
MAD appears to include a rather heterogeneous group of patients.
Previously, it was mentioned that the possibility that MAD is
a prodromal stage of MDD or generalized anxiety disorder needed
to be ruled out (Zinbarg et al., 1994); that is, if MAD appears to be
a prodromal stage of another psychiatric disorder, MAD should be
better regarded a prodromal stage of this disorder rather than calling
it a different diagnostic concept. Previous research has shown that in
primary care, almost half of those with MAD at baseline had devel-
oped a threshold psychiatric disorder after a 1-year follow-up (Barkow
et al., 2004). Thus, MAD was a prodromal stage in about half the
cases. Of note, 27% had developed a depressive disorder, dysthymia,
agoraphobia, panic disorder, or comorbid anxiety and depressive
disorder, whereas another 22% fulfilled criteria of another ICD-10
disorder such as pain disorder, somatization disorder, hypochondriasis,
neurasthenia, or alcohol disorders (Barkow et al., 2004). In addition, the
results of a taxometric analysis reported the development of anxiety and
depressive disorders over time (Schmidt et al., 2007). In the rationale
accompanying the proposed revisions on the DSM-5 Web site, the
progression to full-blown psychiatric disorders is used as an argument
to establish MAD as a diagnostic category in DSM-5 (American Psy-
chiatric Association, 2012a). In our opinion, the progression of MAD
to full-blown disorders suggests that its course may be unfavorable
and that the condition may therefore warrant attention, but it does not
mean that establishing MAD as a separate diagnostic category is the
best way to call attention to the condition. Given that at the time of
presenting with MAD symptoms, the specific future disorder is not
known, subthreshold anxiety and subthreshold depression could be
classified instead. Second, limited diagnostic stability has been reported
when reassessing those with MAD over time. Several studies reported
almost no cases with MAD at baseline that still fulfilled criteria of
MAD at follow-up (Barkow et al., 2004; Spijker et al., 2010). Third,
some previous findings suggest that a substantial proportion of those
with ‘‘MAD’’ experience MAD symptoms in the waxing and waning
course of a threshold depressive disorder or threshold anxiety dis-
order. Roy-Byrne et al. (1994) reported that 95% of the individuals
with subthreshold symptoms in primary care have a lifetime psy-
chiatric diagnosis. Moreover, Piccinelli et al. (1999) reported high
odds ratios (OR) for having a lifetime history of depression (OR, 4.0),
a recent history of depression (OR, 4.8), a lifetime history of panic
disorder (OR, 4.6), or a recent history of panic disorder (OR, 3.7)
in primary care patients with mixed subthreshold anxiety and sub-
threshold depression. To ensure that MAD as a diagnostic cate-
gory would not contain residual symptoms of threshold anxiety
and depressive disorders, those with a current anxiety or depressive
disorder and those with a history of an anxiety disorder (i.e., panic
disorder or generalized anxiety disorder) or depressive disorder
(i.e., major depressive disorder or dysthymic disorder) were excluded
according to the research criteria of the DSM-IV (American Psychiatric
Association, 1994) (Table 1). Whereas Zinbarg et al. (1994) reported
little impact of these exclusion criteria, we found that applying these
exclusion rules resulted in very low annual prevalence rates of 0.6%
for MAD. Moreover, applying these exclusion criteria may select a
less severe group that may not fulfill criteria of clinical relevance, as
suggested by the limited consequences in terms of functioning, care
utilization, and course when applying these exclusion rules (Spijker
et al., 2010). Those with a history of an anxiety or a depressive dis-
order are no longer excluded according to the proposed criteria of
DSM-5, suggesting that those with MAD according to the proposed
criteria of DSM-5 consist of a heterogeneous group of patients in-
cluding many with either prodromal symptoms or residual symp-
toms occurring in the long-term course of threshold disorders.
CONCLUSION
A distinct diagnosis of MAD has been proposed to enable
classification of patients with co-occurring depressive and anxiety
symptoms. Although acknowledging several advantages of a distinct
classification, we argue against the proposed category of MAD for
several reasons. We pointed out that diagnostic criteria applied have
a substantial impact on the prevalence rate. We also argued that cre-
ating such a diagnosis is inconsistent with current nomenclature in
which such a comorbid diagnosis is absent at threshold level and that
evident advantages of classifying MAD over classifying subthreshold
categories are unclear. Finally, we questioned the validity of the
proposed category based on low diagnostic stability over time.
MAD is on the list of disorders to be investigated in field trials
in large academic clinic settings (American Psychiatric Association,
2012b). Although this provides the opportunity to increase knowledge
on several important issues, assessing the prevalence requires studies
in primary care or the general population too.Moreover, the field trials
include only one follow-up evaluation after 4 to12 weeks. Assessing
diagnostic changes over time to gain insight into the validity of the
MAD concept requires longer follow-up studies.
In conclusion, thorough research is needed before considering
to adopt the diagnosis MAD in DSM-5. Moreover, in patients with
a history of an anxiety disorder or depressive disorder, adopting a
longitudinal perspective is more rational. Thus, rather than calling it
a different diagnostic entity, attention should be paid to the early signs
of recurrences and to long-term fluctuations in symptom level of
anxiety and depressive disorders, thus labeling these symptoms as
part of the course trajectories of the anxiety or depressive disorder.
In patients without previous anxiety disorder and depressive disorder
who present with co-occurring anxiety and depressive symptoms
of clinical relevance, these symptoms could be classified as (both)
subthreshold depression and subthreshold anxiety (i.e., Subsyndro-
mal Depressive Condition Not Elsewhere Classified and Unspecified
Anxiety Disorder). In doing so, a consistent classification system at
both threshold and subthreshold levels will be maintained.
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